Cormican Sarah, Kennedy Claire, O'Kelly Patrick, Doyle Brendan, Dorman Anthony, Awan Atif, Conlon Peter
Nephrology, Beaumont Hospital, Dublin, Ireland.
Nephrology and Transplantation, Beaumont Hospital, Dublin, Ireland.
Clin Transplant. 2018 Jan;32(1). doi: 10.1111/ctr.13152. Epub 2017 Dec 4.
Primary focal segmental glomerular sclerosis (p-FSGS) is commonly complicated by recurrence (r-FSGS) post-transplantation. Our objective was to describe Irish outcomes for transplantation after end-stage renal disease (ESRD) due to p-FSGS, specifically rates of, and treatments for, r-FSGS.
Irish patients with biopsy-proven FSGS were identified from the Irish National Kidney Transplant database (1982-2015). Medical record review was performed to identify predictors of r-FSGS and treatments for r-FSGS. Transplant outcomes were compared to outcomes in all renal transplants performed during the same time period using registry data. Demographic and clinical predictors of r-FSGS were identified. Statistical analysis was performed using Stata (version 13, College Station, TX, USA).
Thirty-eight transplant recipients had biopsy-proven p-FSGS, 16 received a second transplant. A total of 3846 transplants formed the comparator group. r-FSGS complicated 60.5% (23/38) of first transplants. Eighty-six percent (10/12) of patients with previous r-FSGS developed recurrent disease after further transplantation. Patients with p-FSGS receiving a first renal transplant had higher rate of graft failure than those with another cause of ESRD (HR 1.9, 95% CI 1.152-3.139). Sixteen patients received immunotherapy for r-FSGS; 12 (86%) had at least partial response, but two (14%) developed significant complications.
We demonstrate high rates of r-FSGS and describe modest success from with treatments for r-FSGS.
原发性局灶节段性肾小球硬化(p-FSGS)在移植后常并发复发(r-FSGS)。我们的目的是描述爱尔兰因p-FSGS导致终末期肾病(ESRD)后的移植结局,特别是r-FSGS的发生率及治疗方法。
从爱尔兰国家肾脏移植数据库(1982 - 2015年)中识别出经活检证实为FSGS的爱尔兰患者。通过病历审查来确定r-FSGS的预测因素及r-FSGS的治疗方法。使用登记数据将移植结局与同期进行的所有肾移植的结局进行比较。确定r-FSGS的人口统计学和临床预测因素。使用Stata(美国德克萨斯州大学站第13版)进行统计分析。
38例移植受者经活检证实为p-FSGS,16例接受了二次移植。共有3846例移植构成对照组。r-FSGS使60.5%(23/38)的首次移植出现并发症。既往有r-FSGS的患者中,86%(10/12)在再次移植后出现复发性疾病。因p-FSGS接受首次肾移植的患者移植失败率高于因其他ESRD病因的患者(风险比1.9,95%置信区间1.152 - 3.139)。16例患者接受了r-FSGS免疫治疗;12例(86%)至少有部分反应,但2例(14%)出现严重并发症。
我们证明了r-FSGS的高发生率,并描述了r-FSGS治疗取得的适度成功。